Société Française de Dermatologie

Chi-PsoCov

Chi-PsoCov

Chi-PsoCov

Chi-PsoCov is an international registry for dermatologists to report outcomes of COVID-19 in children with psoriasis.

The objectives of the Chi-PsoCoV (Children with psoriasis and COVID-19) registry, conducted in psoriatic children.

  • The impact of SARS-Cov2 infection on psoriasis:
    • Psoriasis flare or even psoriasis de novo after infection
    • Correlation between symptom severity and psoriasis flares
  • The impact of psoriasis and its treatments on the risk of developing a severe form of COVID-19

Inclusion criteria are:

  • child
  • with psoriasis (confirmed by a dermatologist)
    • before infection / SARS-CoV-2
    • or psoriasis developed within one month after infection with SARS-CoV-2 (de novo psoriasis)
    • whatever the severity of the disease (even psoriasi controled by or xwothout treatment) and the treatment
  • have contracted SARS-CoV-2 with or without symptoms:
    • confirmed cases (PCR, serology, antigenic test, or chest CT-scan)
    • suspected cases with sufficient data for infection in the child:
      • confirmed cases in the family home
      • highly suspected cases (characteristic symptoms) in the family, but not confirmed (especially before the establishment of systematic tests):
      • contact case (school for example) with suggestive symptoms
    • onset of symptoms (if symptomatic) of COVID-19 for at least 1 month

Non-inclusion criteria are:

  • refusal expressed by family and/or children to collect the information

We are grateful for your contribution. Please report your cases of COVID-19 in children with psoriasis whatever its severity and its treatment, using this form. 

Recruitment will be done by dermatologists who follow psoriatic children.
We will provide regular information on all reported cases.

Thank you,

Dr. Emmanuel Mahé, Pr Anna Belloni Fortina, Pr Anne-Claire Burztejn, Pr Hervé Bachelez, Dr Jinane Zitouni

Scientific Committee

Coordination:

Dr. Emmanuel Mahé , Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France (1,2)

Members:

  • Prof. Hervé Bachelez, Service de Dermatologie, CHU St-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France (1)
  • Dr. Alain Beauchet, Département de Santé Publique, CHU Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, Paris
  • Prof. Anna Belloni Fortina, Regional Center for Pediatric Dermatology and Genodermatoses, Department of Medicine DIMED, University of Padua, Padova, Italy (3)
  • Prof. Anne-Claire Bursztejn, Service de Dermato-Allergologie, Hôpitaux de Brabois, Vandœuvre-lès-Nancy, France (1,2)
  • Dr. Jinane Zitouni, Service de Dermatologie et Médecine Vasculaire, Hôpital Victor Dupouy, Argenteuil, France

1. Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie (SFD)
2. Research Group of the Société Française de Dermatologie Pédiatrique (SFDP)
3. Società Italiana di Dermatologia Pediatrica (S.I.Der.P.)

Report a case

  

Current data (19 January 2022)

Total number of cases reported

110

Countries that assessed children, n

 

Argentina

1

France

55

Greece

India

4

Italy

11

Mexico

2

Netherland

1

Poland

13

Portugal

2

Romania

3

Russia

6

Sweden

1

Turkey

5

United Kingdom

5

   

Children  

108

Girls / boys 

50 / 58

Age (mean ± SD) 

12.7 ± 3.7 y

  

  

Psoriasis before COVID-19

 

Age of onset of psoriasis (mean ± SD)

7.4 ± 4.0 y

Plaque psoriasis

71

Nail psoriasis

46

Psoriasis arthritis

7

   

COVID-19

 

Confirmed / suspected

98 / 12

N° of COVID-19 / child

 

1

108

2

2

Symptoms

67

Hospitalization

6

Long-Covid

2

   

Since COVID-19 onset, the psoriasis has

 

Improved

1

Worsened, with same psoriasis phenotype

13

Worsened, phenotype changed (guttate ...)

1

Remained same

80

Psoriasis de novo

7

No information

8

   

Systemic medications for psoriasis at time of onset of COVID-19

 

Phototherapy

6

Methotrexate

15

Acitretin

6

Cyclosporine

1

Apremilast

1

Etanercept

4

Adalimumab

12

Ustekinumab

14

Risankizumab

1

Secukinumab

1

Publications (rules)

The objective is to publish this work in an international dermatological journal.

The following rules are proposed by the Scientific Committee (SC):

  • 1st: Dr Jinan Zitouni (student carrying out the work)
  • 2nd author: biostatistician: Dr Alain Beauchet
  • Latest author: Dr Emmanuel Mahé (project coordinator)
  • The members of the SC will co-sign the publication. The ranks will be discussed within the SC, depending on the number of inclusions
  • Other authors: in decreasing order of the number of children included in the study, up to a maximum of 10 to 20 authors (a larger number of authors may be discussed depending on the journal).
  • All investigators who have included at least one patient will appear in the list of authors, and will be cited on PubMed.
  • If there are several investigators in a center, either a single author will be assigned to the center (to be defined by the center), or the 2 authors may sign according to the rule: in proportion to the number of children included by each investigator
  • The affiliations “Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie”, “Research Group of the Société Française de Dermatologie Pédiatrique”, and “Società Italiana di Dermatologia Pediatri” will appear at the end of the list of authors